Association Between S-1 Treatment Duration and Disease Control in Advanced Non-small-cell Lung Cancer
Cancer Diagnosis & Prognosis · 2026-11-01 · 6 (6) · 988-995
DOI: 10.21873/cdp.10601 ↗Abstract
Background/Aim: S-1 monotherapy is used for a subset of patients with advanced non-small-cell lung cancer (NSCLC); however, predictors of prolonged treatment and survival remain unclear. The aim of this study was to investigate clinical factors associated with extended S-1 treatment and clinical outcomes in patients with advanced NSCLC. Patients and Methods: We retrospectively reviewed the data of 32 patients with stage IIIB/IV or recurrent NSCLC who received S-1 monotherapy at Kanazawa Medical University Hospital from January 2015 and December 2025. Patients were classified into a long-term treatment group (≥90 days, n=13) or a short-term treatment group (
EUVIMED